Acute Promyelocytic Leukemia Treatment and Management

Definition and Epidemiology

Acute Promyelocytic Leukemia (APL) constitutes approximately 10% of all acute myeloid leukemia (AML) cases with an age-adjusted annual incidence of 0.23 per 100,000 persons, according to the National Comprehensive Cancer Network 1, 2
The median age at diagnosis is 44 years, which is younger than the median age of 67 years for other AML subtypes, as reported by the National Comprehensive Cancer Network 1, 2
APL is distinguished cytogenetically by the presence of the translocation t(15;17)(q24.1;q21.1), which creates the PML-RARA fusion gene, as identified by the National Comprehensive Cancer Network and Annals of Oncology 1, 3

APL is considered a medical emergency due to the high risk of life-threatening hemorrhage from severe coagulopathy, as stated by Blood 4, 5
Severe coagulopathy with bleeding manifestations is a common presentation in APL patients, according to Blood and the National Comprehensive Cancer Network 6, 1
Bone marrow aspirate is essential for diagnosis, and morphologic features typically show abnormal promyelocytes with hypergranular or microgranular forms, as described by Blood 6, 7, 8
Immunophenotyping shows characteristic features, including CD34-/+ heterogeneous, CD117-/+ dim, and HLADR-/+ dim, as reported by Blood 8

Risk stratification is based primarily on white blood cell (WBC) count, with low-risk defined as WBC count ≤10,000/mcL, intermediate-risk often grouped with low-risk, and high-risk defined as WBC count >10,000/mcL, according to the National Comprehensive Cancer Network 1, 2

The National Comprehensive Cancer Network recommends starting all-trans retinoic acid (ATRA) immediately upon clinical suspicion of APL, even before genetic confirmation, as stated by Blood 6, 4
Aggressive supportive care to manage coagulopathy is critical to prevent early hemorrhagic death, as emphasized by Blood 6, 7
Standard induction regimens combine ATRA with anthracycline-based chemotherapy, with complete remission rates exceeding 90%, as reported by the National Comprehensive Cancer Network 1, 2
ATRA-based maintenance therapy is generally recommended, with more than 80% of APL patients able to be cured with current treatment approaches, according to the National Comprehensive Cancer Network 1, 2

Pseudotumor cerebri is more common in children (11%) receiving ATRA, and can be managed with steroids and dose reduction if necessary, as reported by Blood 4, 5
Early death from hemorrhage remains the primary cause of treatment failure, as stated by the National Comprehensive Cancer Network 1, 2